High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
about
From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various ApplicationsDeconvoluting Kinase Inhibitor Induced Cardiotoxicity.The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.Acquired long QT syndrome and phosphoinositide 3-kinase.Paying the Toll in Nuclear Reprogramming.Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.Multiscale technologies for treatment of ischemic cardiomyopathy.Omics-Based Platform for Studying Chemical Toxicity Using Stem Cells.Differentiation and Contractile Analysis of GFP-Sarcomere Reporter hiPSC-Cardiomyocytes.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.CRISPR/Cas9-Mediated Fluorescent Tagging of Endogenous Proteins in Human Pluripotent Stem Cells.[Leukocyte count of puerperal sows].Drug toxicity: Cardiac safety index for TKIs.Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients.The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications.Genetic and Tissue Engineering Approaches to Modeling the Mechanics of Human Heart Failure for Drug DiscoveryModeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells
P2860
Q33847517-8D9F2677-3E55-4D9C-ACB9-DFCF01D972A6Q38814429-8D0C6B9D-019F-4A98-B864-BB33C9710E90Q39231153-677F099D-CB07-4894-9758-7261BF2A9F41Q39421620-F04D1821-B9A6-4D7E-BD89-90DA7585EFB1Q41458562-3F2DD93C-0464-4C9C-81DC-72A566134C9DQ41688591-E91891F5-53D3-4BF2-B0B7-DECE463FBB3AQ46454164-5ACF0853-D761-447B-B2FA-DB55322D7BC5Q47271495-4F3E4903-15B0-4BB4-A2EF-DA9A33A808F3Q48505612-8BCFE64A-2D48-4512-B49C-6B08B15969FBQ49315568-BE920E24-FF3D-4852-A5E4-82AC3EF11568Q49823752-20D6F093-D335-4584-8D77-7700A3044D00Q50300835-3E88D7A1-D64C-48B8-9CEA-968568B21146Q51081513-0A6A3204-CE60-4721-A7BC-DC72FA4A667BQ52560413-EF34D21D-5EDB-442C-AB97-E511391ACC91Q52723478-23917EC0-0295-41EF-A822-247A664129F4Q55274551-E0954C80-B6DF-4679-B121-38664DDFFB71Q55339567-216BEACF-C7A6-46F3-A8D0-483F2B1AEE85Q55499094-BBDB4D0E-BC42-4E92-9EA7-E51051B0D6CCQ57072496-EF5993E2-443C-48AD-9751-CE01CAF39EF1Q57490090-B13E14D7-7047-4F28-AD90-BE1FA59F90A3
P2860
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
High-throughput screening of t ...... nduced pluripotent stem cells.
@ast
High-throughput screening of t ...... nduced pluripotent stem cells.
@en
type
label
High-throughput screening of t ...... nduced pluripotent stem cells.
@ast
High-throughput screening of t ...... nduced pluripotent stem cells.
@en
prefLabel
High-throughput screening of t ...... nduced pluripotent stem cells.
@ast
High-throughput screening of t ...... nduced pluripotent stem cells.
@en
P2093
P2860
P50
P1476
High-throughput screening of t ...... induced pluripotent stem cells
@en
P2093
Alexandra Holmström
Alice C Fan
Anusha Kumar
Elena Matsa
Jared M Churko
Javid J Moslehi
Nazish Sayed
Paul W Burridge
Praveen Shukla
P2860
P356
10.1126/SCITRANSLMED.AAF2584
P407
P577
2017-02-01T00:00:00Z